CD8A and cancer: Bortezomib (BTZ) can kill tumor cells via the NF-κB signaling pathway, activate caspase-3 to inhibit cancer-associated fibroblast (CAF) activity, and enhance CD8+ T cell function by modulating the expression of immune stimulatory factors, thereby treating BRCA (Liu et al., 2023).